Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data – NEW YORK, November 21, 2024 – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, is proud…
Vancouver, British Columbia, November 4, 2024 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)announcesthat further to its news release of October 18, 2024, the Company has closed a non-brokered private placement of1,612,902common shares in the capital of the Company (“Shares”) at a price of USD$21.70 per Sharefor aggregate gross proceeds…
NEW YORK AND VANCOUVER, October 21, 2024 – Bright Minds Biosciences Inc. (Bright Minds or the Company)(NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced that it is once again collaborating with Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an Artificial Intelligence (AI) company developing innovative solutions that improve…
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Vancouver, British Columbia, October 18, 2024 – Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) is pleased to announce a non-brokered…
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, October 16, 2024—Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data from…
BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, October16, 2024—Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other CNS disorders, is excited to announce positive data forthe…
Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience NEW YORK, October 3, 2024 Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering company focused on developing highly…
Bright Minds Biosciences announced the initiation of Phase 2 clinical trial of BMB-101 in a group of drug-resistant epilepsies and will discuss the details of the BREAKTHROUGH clinical trial on September 25th The event will feature Epilepsy KOLs to discuss the unmet needsfor epilepsy treatment. BMB-101 is the first 5-HT2C agonist in clinical studies designed…
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonismprovides an improved mechanism of action for chronic dosing Financial runway extending into 2026 enabling key data readout Conference call& KOL Event…
×
"*" indicates required fields